Investor Relations

Latest Financial Results

Q1 2021

Quarter Ended March 31, 2021

Latest Annual Filing

For Fiscal Year Ending December 31, 2020

Company Overview

Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Todos owns 19.99% of Breakthrough Diagnostics, Inc., a joint venture with Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) that is developing the LymPro Test®, a blood test for diagnosing Alzheimer’s disease. Todos has exercised its option to acquire Breakthrough, and expects to close on that transaction in the first half of 2020. Todos has also entered into an exclusive option to acquire breast cancer blood testing company Provista Diagnostics, Inc. that is commercializing the Videssa® breast cancer blood test.

IR Contacts

Company

Todos Medical Ltd.
121 Derech Menachem Begin, 30th Floor
Tel Aviv 6701203
Israel
T: +972-73-207-7259

Todos Medical U.S.A.
40 Wall Street, Suite 2702
New York, NY 10005
T: +1-917-983-4229

Investor Relations

Richard Galterio
T: (917) 768-5996 ext 106
rich.g@todosmedical.com

Transfer Agent

Worldwide Stock Transfer, LLC
One University Plaza
Suite 505
Hackensack, NJ 07601
T: 201-820-2008
F: 201-820-2010